Overview

Folate Supplementation in Schizophrenia

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
This study aims to examine factors potentially contributing to differences in blood folate, homocysteine or B12 levels between schizophrenia patients, to test the hypothesis that low folate is associated with negative symptoms, and to examine the efficacy of folate supplementation for reducing negative symptoms.
Phase:
Phase 4
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
National Alliance for Research on Schizophrenia and Depression
Treatments:
Folic Acid
Vitamin B Complex